CHEK1 and lymphoma: We also showed that CX-5461 in combination with dual inhibition of checkpoint kinases 1/2 (CHK1/2) downstream of ATM and ATR signalling significantly enhanced the therapeutic outcome of p53-null MYC-driven lymphoma in vivo19.